The Eastman Kodak Company announced a joint venture with a large French drug maker yesterday, as expected, and in so doing may have found a virtually cost-free solution to a nagging problem. Ever since buying Sterling Drug in 1988 for $5.1 billion, Kodak has had difficulty convincing investors that the money was well spent.